Novel 5-(nitrothiophene-2-yl)-1,3,4-Thiadiazole Derivatives : Synthesis and Antileishmanial Activity against promastigote stage of Leishmania major
In this study, a series of novel compounds based on 5-(5-nitrothiophene-2-yl)-1,3,4-thiadiazole possessing (het) aryl thio pendant at C-2 position of thiadiazole ring is developed and evaluated as antileishmanial agents using MTT colorimetric assay. 10 New compounds containing aryl and heteroaryl derivatives, started from thiophene-2-carbaldehyde in five steps, were synthesized in good to excellent yields and characterized by 1H-NMR, 13C-NMR, and IR spectroscopy. Through the compounds 6a-j, methylimidazole containing derivative 6e was recognized as the most active compound against L. major promastigotes exhibiting IC50 values of 11.2µg/mL and 7.1µg/mL after 24 and 48 h, respectively. This compound is > 4 fold more effective than Glucantime as a standard drug (IC50 = 50 µg/mL after 24 h and 25 µg/mL after 48 h).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Iranian journal of pharmaceutical research : IJPR - 18(2019), 4 vom: 09., Seite 1816-1822 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sadat-Ebrahimi, Seyed Esmail [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1 |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.22037/ijpr.2019.14547.12476 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307713989 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307713989 | ||
| 003 | DE-627 | ||
| 005 | 20231225130151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.22037/ijpr.2019.14547.12476 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1025.xml |
| 035 | |a (DE-627)NLM307713989 | ||
| 035 | |a (NLM)32184848 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sadat-Ebrahimi, Seyed Esmail |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel 5-(nitrothiophene-2-yl)-1,3,4-Thiadiazole Derivatives |b Synthesis and Antileishmanial Activity against promastigote stage of Leishmania major |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a In this study, a series of novel compounds based on 5-(5-nitrothiophene-2-yl)-1,3,4-thiadiazole possessing (het) aryl thio pendant at C-2 position of thiadiazole ring is developed and evaluated as antileishmanial agents using MTT colorimetric assay. 10 New compounds containing aryl and heteroaryl derivatives, started from thiophene-2-carbaldehyde in five steps, were synthesized in good to excellent yields and characterized by 1H-NMR, 13C-NMR, and IR spectroscopy. Through the compounds 6a-j, methylimidazole containing derivative 6e was recognized as the most active compound against L. major promastigotes exhibiting IC50 values of 11.2µg/mL and 7.1µg/mL after 24 and 48 h, respectively. This compound is > 4 fold more effective than Glucantime as a standard drug (IC50 = 50 µg/mL after 24 h and 25 µg/mL after 48 h) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 1 | |
| 650 | 4 | |a 3 | |
| 650 | 4 | |a 4-thiadiazole | |
| 650 | 4 | |a Leishmaniasis | |
| 650 | 4 | |a MTT assay | |
| 650 | 4 | |a Promastigote | |
| 650 | 4 | |a Synthesis | |
| 700 | 1 | |a Mirmohammadi, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Mojallal Tabatabaei, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Azimzadeh Arani, Marjan |e verfasserin |4 aut | |
| 700 | 1 | |a Jafari-Ashtiani, Sogol |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemian, Mahsa |e verfasserin |4 aut | |
| 700 | 1 | |a Foroumadi, Parham |e verfasserin |4 aut | |
| 700 | 1 | |a Yahya-Meymandi, Azadeh |e verfasserin |4 aut | |
| 700 | 1 | |a Moghimi, Setareh |e verfasserin |4 aut | |
| 700 | 1 | |a Moshafi, Mohammad Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Norouzi, Peiman |e verfasserin |4 aut | |
| 700 | 1 | |a Kabudanian Ardestani, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Foroumadi, Alireza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Iranian journal of pharmaceutical research : IJPR |d 2010 |g 18(2019), 4 vom: 09., Seite 1816-1822 |w (DE-627)NLM232822573 |x 1726-6890 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2019 |g number:4 |g day:09 |g pages:1816-1822 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.22037/ijpr.2019.14547.12476 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2019 |e 4 |b 09 |h 1816-1822 | ||